Metlinka

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Metlinka (Metformin Hydrochloride, Sitagliptin)

Q: What is Metlinka used for?

Metlinka is prescribed for the treatment of type 2 diabetes mellitus. It helps lower elevated blood glucose levels by improving insulin sensitivity and enhancing insulin secretion, and is intended to be used together with diet and exercise as part of a comprehensive diabetes management plan.

Q: How does Metformin and Sitagliptin work in Metlinka?

Metlinka combines metformin, which decreases hepatic glucose production and increases peripheral insulin sensitivity, with sitagliptin, a DPP‑4 inhibitor that raises incretin hormone levels. The combined effect reduces blood glucose by both limiting glucose output from the liver and promoting insulin release when glucose is high.

Q: What is the usual dose of Metlinka?

The dosage of Metlinka is individualized by a qualified healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary dose adjustments.

Q: Is Metlinka safe during pregnancy or breastfeeding?

Safety of Metlinka in pregnancy and lactation has not been fully established. Metformin may be used when the potential benefit justifies the risk, but sitagliptin is generally avoided. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their physician.

Q: How do I order Metlinka from GNH India?

To order Metlinka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Metlinka compare with other antidiabetic therapies?

Metlinka offers a dual mechanism by combining a biguanide with a DPP‑4 inhibitor, providing both insulin‑sensitising and insulin‑secretagogue effects. Compared with monotherapy agents, this combination can achieve greater HbA1c reduction and may reduce the need for additional drugs, while maintaining a safety profile similar to its individual components.

Q: What are the storage and handling requirements for Metlinka?

Metlinka should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Q: How is Metlinka administered?

Metlinka is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Q: What are the most serious risks associated with Metlinka?

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycaemia, especially when used with other glucose‑lowering agents. Pancreatitis and allergic reactions are also rare but important to monitor for.

Q: Who should not use Metlinka?

Metlinka is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those receiving iodinated contrast agents without appropriate discontinuation of metformin.

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metlinka, is a Biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients.

GNH India supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Swyssi Ag

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metlinka is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.
Type 2 diabetes mellitus: improves glycaemic control when used with diet and exercise, reducing fasting plasma glucose and HbA1c levels.

How It Works

Metlinka combines two complementary actions: metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin blocks the dipeptidyl peptidase‑4 enzyme, raising endogenous incretin levels that stimulate glucose‑dependent insulin release and suppress glucagon secretion, together lowering blood glucose concentrations.

Side Effects

Metlinka may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

Nausea
Diarrhoea
Abdominal discomfort
Headache
Mild hypoglycaemia (especially when combined with other antidiabetics)
Upper respiratory tract infection

Serious or Rare Side Effects

Lactic acidosis
Severe hypoglycaemia
Pancreatitis
Acute renal failure
Hepatic dysfunction
Anaphylactic reactions

Precautions & Warnings

Before prescribing Metlinka, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal impairment: assess kidney function and adjust dose or avoid if eGFR <30 mL/min/1.73 m².
Hepatic disease: use with caution due to increased risk of lactic acidosis.
Heart failure: monitor for signs of fluid overload and metabolic acidosis.
Concomitant contrast media: discontinue metformin before and after iodinated contrast procedures.
Store at ambient temperature (below 25°C): keep in the original container, protect from moisture and light.

Avoid Interactions

Metlinka can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Iodinated contrast agents: increase risk of metformin‑associated lactic acidosis; discontinue metformin before and after use.
Insulin or sulfonylureas: may cause severe hypoglycaemia; dose adjustments required.

Moderate Interactions (Monitor Closely)

Cimetidine: can raise sitagliptin plasma concentrations.
Rifampicin: may reduce sitagliptin exposure.
Diuretics: may affect renal clearance of metformin, necessitating monitoring of renal function.

Frequently Asked Questions

Metlinka is prescribed for the treatment of type 2 diabetes mellitus. It helps lower elevated blood glucose levels by improving insulin sensitivity and enhancing insulin secretion, and is intended to be used together with diet and exercise as part of a comprehensive diabetes management plan.

Metlinka combines metformin, which decreases hepatic glucose production and increases peripheral insulin sensitivity, with sitagliptin, a DPP‑4 inhibitor that raises incretin hormone levels. The combined effect reduces blood glucose by both limiting glucose output from the liver and promoting insulin release when glucose is high.

The dosage of Metlinka is individualized by a qualified healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary dose adjustments.

Safety of Metlinka in pregnancy and lactation has not been fully established. Metformin may be used when the potential benefit justifies the risk, but sitagliptin is generally avoided. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their physician.

To order Metlinka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metlinka offers a dual mechanism by combining a biguanide with a DPP‑4 inhibitor, providing both insulin‑sensitising and insulin‑secretagogue effects. Compared with monotherapy agents, this combination can achieve greater HbA1c reduction and may reduce the need for additional drugs, while maintaining a safety profile similar to its individual components.

Metlinka should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metlinka is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycaemia, especially when used with other glucose‑lowering agents. Pancreatitis and allergic reactions are also rare but important to monitor for.

Metlinka is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those receiving iodinated contrast agents without appropriate discontinuation of metformin.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 07 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.